MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management

Figure 4

CAPAN-2-tumour-bearing mice injected with ⁸⁹Zr-DFO-LEM2/15. (a) Representative PET/CT images of a mouse with subcutaneous CAPAN-2 xenograft injected with ⁸⁹Zr-DFO-LEM2/15 acquired at 1 and 7 days after injection. Tumour locations are indicated by white arrows. (b) Immunohistochemistry of tumour tissue from xenografted mice. MT1-MMP was detected using LEM2/15 antibody. Scale bar: 100 µm. (c) Tumour uptake (expressed as %ID/g) of ⁸⁹Zr-DFO-LEM2/15 as quantified by PET imaging. (d) Tumour-to-blood and tumour-to-background ratios derived from PET images. (e) Liver and bone uptake of ⁸⁹Zr-DFO-LEM2/15 as quantified by PET imaging at different times after injection.

(a)

(b)

(c)

(d)

(e)